Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Donald Trump says he has been indicted on federal charges in documents probe
    • Ukraine sends western tanks into battle as counter-offensive gets under way
    • Erdoğan taps former Goldman Sachs banker to head Turkey’s central bank
    • Canadian wildfire smoke jars New York with ‘movie of the future’
    • Norway seeks to open vast ocean area to deep-sea mining
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Goldman, Exane and Schroders cut ties with Odey Asset Management after assault claims
      • FCA investigates Odey Asset Management
      • Anne Boden stepped down as Starling CEO after investor clash
      • LetterOne chair Mervyn Davies receives bumper payout after Russian oligarchs’ exit
      • The Pirelli boss taking on China’s Communist party
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Live news updates from June 9: Trump charged with 37 counts, Boris Johnson to stand down from parliament
      • Goldman, Exane and Schroders cut ties with Odey Asset Management after assault claims
      • FCA investigates Odey Asset Management
      • Norway seeks to open vast ocean area to deep-sea mining
      • Binance US to suspend dollar transactions after payment partners pause activity
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • How US cities became one big parking lot
      • Apple’s Vision Pro headset has made the metaverse feel outdated
      • Trump indictment brings him closer to the danger zone
      • Ukraine’s dam explosion is a red line: Russia must feel the consequences
      • What an amusement park can teach us about central banks
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Too good to be true? The fake recruiters targeting jobseekers
      • Can a virtual PA turbocharge your career?
      • Anti-monarchist Graham Smith: The British royals are ‘tax-funded Kardashians’
      • FT business books: what to read this month
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • How Crispin Odey evaded sexual assault allegations for decades
      • François Hollande: ‘Putin cannot be seduced. He respects force’
      • Grand Seiko’s rock star of watchmaking
      • Don’t blame us for AI’s threat to humanity, we’re just the technologists
      • Confessions of a food award judge
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Hannah Kuchler

    Global Pharmaceuticals Correspondent

    Hannah Kuchler reports on the pharmaceutical industry and the Covid-19 pandemic. She previously covered US pharma and biotech in New York and the technology industry in Silicon Valley.
    Email Hannah Kuchler @hannahkuchler  on Twitter (link opens in a new browser window)

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Sunday, 4 June, 2023
      News in-depthAstraZeneca PLC
      AstraZeneca defies geopolitics to bet on China

      Drugmaker seeks opportunities due to ageing population and burgeoning biotech industry

    • Sunday, 28 May, 2023
      InterviewLeadership
      Wellcome Leap’s Regina Dugan: ‘Odds are irrelevant, if what you’re trying to do is important’

      The former head of the US defence department’s research agency was behind big bets on mRNA technology

    • Friday, 26 May, 2023
      Covid-19 vaccines
      Brussels and Pfizer agree deal to cut supply of Covid vaccines

      Revised contract addresses concerns over costly glut of unwanted shots as public health threat wanes

    • Thursday, 25 May, 2023
      Drug prices
      No ‘magic wand’ for financial pressures, Hunt tells pharma groups

      UK unveils reforms worth £650mn to boost the life sciences sector

    • Wednesday, 24 May, 2023
      Biotech
      UK to announce funding boost for life sciences

      Government seeks to win over pharma groups with new investments in genomics research and drug manufacturing

    • Wednesday, 17 May, 2023
      Mergers & Acquisitions
      M&A crackdown a ‘disaster’ for pharma sector, Pfizer executive warns

      Development chief raises worry over innovation after FTC sues to block Amgen-Horizon deal

    • Wednesday, 17 May, 2023
      Amgen Inc
      Regeneron boss backs attempt to block $28bn Amgen acquisition

      Leonard Schleifer supportive of FTC’s lawsuit against takeover of Horizon Therapeutics

    • Friday, 12 May, 2023
      UK politics & policy
      ‘Cultural sniffiness’ over profit is hurting NHS drug trials, Labour warns

      Shadow health secretary sets out plan to boost clinical research

    • Monday, 8 May, 2023
      Biotech
      UK biotech start-up raises $130mn to solve capacity bottleneck

      Ascend is buying up manufacturing facilities from cash-strapped cell and gene therapy companies

    • Thursday, 4 May, 2023
      AstraZeneca PLC
      AstraZeneca chair says it is paying CEO enough to ward off US rivals

      Drugmaker’s chief executive Pascal Soriot had talks last year about a role with US group Biogen

    • Monday, 1 May, 2023
      Healthcare
      UK partnerships with life sciences groups threatened by NHS pressures

      Hurdles facing drug trials point to challenges for Britain’s drive for innovation

    • Sunday, 30 April, 2023
      Pharmaceuticals sector
      GSK struggles to make investors believe its growth story

      Industry watchers say UK-listed rival AstraZeneca has a stronger pipeline and benefits from its oncology expertise

    • Thursday, 27 April, 2023
      AstraZeneca PLC
      AstraZeneca hunts for more China deals after signing partnerships

      Drugmaker hails innovative biotech groups and says market is open to foreign buyers

    • Wednesday, 26 April, 2023
      Pharmaceuticals sector
      EU aims to create ‘single market for medicines’ with overhaul of pharma rules

      Revamp that would cut drugmakers’ years of market exclusivity meets fierce opposition from sector

    • Wednesday, 26 April, 2023
      GSK PLC
      GSK sales fall after demand for Covid treatment plummets

      US regulators say drugmaker’s Xevudy fails to tackle most prevalent variants of coronavirus

    • Tuesday, 25 April, 2023
      Novartis AG
      Novartis chief criticises EU move to control pharma licensing in emergencies

      Vas Narasimhan warns giving Brussels power over drug manufacturing during crises will hit investment

    • Monday, 24 April, 2023
      EU business regulation
      EU outlines plan to take control of medicine production in health crises

      Proposal for compulsory licensing risks ire of pharma groups keen to protect patents and revenue

    • Saturday, 22 April, 2023
      Pharmaceuticals sector
      Germany clashes with other EU states on pharma regulation overhaul

      Berlin warns shortening time before generic drugs are allowed to market will stifle industry investment

    • Thursday, 20 April, 2023
      Bayer AG
      Activist investor ramps up pressure on incoming Bayer boss

      Bluebell Capital Partners calls for conglomerate’s break-up and boardroom reshuffle ahead of AGM

    • Tuesday, 18 April, 2023
      GSK PLC
      GSK bets on cough drug with $2bn deal for Canadian biotech

      UK pharma group agrees to buy Bellus Health in effort to strengthen pipeline

    • Sunday, 16 April, 2023
      Biotech
      Gates Foundation makes unusual investment in experimental cancer trial

      Smart Immune is developing technology it hopes will help patients rebuild their immune systems

    • Thursday, 13 April, 2023
      Medical science
      Adopt ‘pop-up’ model to boost clinical trials, UK review argues

      New system could be modelled on Covid-19 vaccinations to ease pressure on hospitals

    • Wednesday, 12 April, 2023
      ReviewBooks
      Women’s health — doctor doesn’t always know best

      From anorexia to heart attacks: two books, by Hadley Freeman and Marieke Bigg, highlight how medicine fails to understand women and girls

    • Tuesday, 11 April, 2023
      FT News Briefing podcast10 min listen
      Rise of the Russian informer

      Corporate America faces its sharpest drop in profits since the beginning of the Covid pandemic

    • Monday, 10 April, 2023
      Eli Lilly & Co
      Eli Lilly warns EU will miss out on key drugs under planned change to patent rules

      Chief executive says draft plan to cut market exclusivity protection could make pursuing some treatments unviable

    Previous page You are on page 1 Next page

    Be part of FT Community

    Discover unmissable flagship events and members only communities to expand your thinking and elevate your career

    FT Live
    Health Technology Summit
    Transforming Life Sciences & Digitising Healthcare
    Thursday, 30th NovemberOnline
    Learn more about FT Community

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsFT Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In